Lynn M Yee1, Danny Wu. 1. From the Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California.
Abstract
BACKGROUND: Labetalol is commonly used for control of hypertension in pregnancy. A component of the workup for new-onset hypertension in pregnancy often includes a urine drug screen. A labetalol metabolite is structurally similar to amphetamine and methamphetamine, thus causing potential cross-reactivity in drug immunoassays. CASES: We present one case of cocaine-induced hypertensive crisis superimposed on chronic hypertension and two cases of severe preeclampsia for which patients required escalating doses of labetalol for hypertension, with subsequent false-positive amphetamine urine drug screen results. CONCLUSION: In pregnant women requiring labetalol for treatment of hypertensive disease, a urine drug screen may be falsely positive for amphetamines and methamphetamines. Providers should be cognizant of this possibility when interpreting the results of urine drug screens.
BACKGROUND:Labetalol is commonly used for control of hypertension in pregnancy. A component of the workup for new-onset hypertension in pregnancy often includes a urine drug screen. A labetalol metabolite is structurally similar to amphetamine and methamphetamine, thus causing potential cross-reactivity in drug immunoassays. CASES: We present one case of cocaine-induced hypertensive crisis superimposed on chronic hypertension and two cases of severe preeclampsia for which patients required escalating doses of labetalol for hypertension, with subsequent false-positive amphetamine urine drug screen results. CONCLUSION: In pregnant women requiring labetalol for treatment of hypertensive disease, a urine drug screen may be falsely positive for amphetamines and methamphetamines. Providers should be cognizant of this possibility when interpreting the results of urine drug screens.
Authors: Stephanie J Marin; Kelly Doyle; Annie Chang; Marta Concheiro-Guisan; Marilyn A Huestis; Kamisha L Johnson-Davis Journal: J Anal Toxicol Date: 2015-09-04 Impact factor: 3.367
Authors: Christina D Martinez-Brokaw; Joshua B Radke; Joshua G Pierce; Alexandra Ehlers; Sean Ekins; Kelly E Wood; Jon Maakestad; Jacqueline A Rymer; Kenichi Tamama; Matthew D Krasowski Journal: BMC Clin Pathol Date: 2019-02-18
Authors: Kelly E Wood; Lori L Sinclair; Carolyn D Rysgaard; Frederick G Strathmann; Gwendolyn A McMillin; Matthew D Krasowski Journal: BMC Pregnancy Childbirth Date: 2014-07-29 Impact factor: 3.007
Authors: Matthew D Krasowski; Andy Schriever; Gagan Mathur; John L Blau; Stephanie L Stauffer; Bradley A Ford Journal: J Pathol Inform Date: 2015-07-28